Prostate Cancer Mortality and Use of 5-Alpha Reductase Inhibitors [PDF]
The World Journal of Men's Health, 2020 Cara A. Foldes +2 more
doaj +5 more sources
Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review [PDF]
Dermatology and Therapy, 2023 Finasteride and dutasteride are 5-alpha reductase selective inhibitors (5ARIs). They were introduced as therapeutic agents for the treatment of benign prostatic hyperplasia in 1992 and 2002, respectively; finasteride has also been approved for the ...
Mariana Escamilla-Cruz +3 more
doaj +2 more sources
5-alpha reductase inhibitors and MRI prostates: actively reducing prostate sizes and ambiguity [PDF]
BMC Urology, 2023 Background Magnetic resonance imaging (MRI) scans are increasingly first-line investigations for suspected prostate cancer, and essential in the decision for biopsy.
Ziting Wang +5 more
doaj +2 more sources
Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis [PDF]
International Neurourology JournalPurpose Alpha-blockers and 5-alpha reductase inhibitors (5ARIs) are well-established treatments for symptoms of benign prostatic hyperplasia (BPH). Despite their therapeutic benefits, concerns have been raised regarding a potential association between ...
Karmenia Jessica Kurnia Niaga +7 more
doaj +2 more sources
Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil [PDF]
BMC UrologyBackground Inconsistent monitoring of prostate-specific antigen in patients receiving 5-alpha reductase inhibitors for lower urinary tract symptoms/benign prostate enlargement may affect prostate cancer outcomes.
Juan Manuel Palacios +7 more
doaj +2 more sources
Using 5 alpha reductase inhibitors safely: What primary care physicians need to know [PDF]
Journal of Family Medicine and Primary Care5 Alpha Reductase Inhibitor (ARI) is a widely used class of medication; for benign prostatic hypertrophy, androgenetic alopecia and hirsutism. While generally considered safe, ARIs class of medication does have a number of side effects, which can ...
Senthil R. Meenrajan
doaj +2 more sources
5-alpha reductase inhibitors use in prostatic disease and beyond. [PDF]
Transl Androl Urol, 2023 5-alpha reductase inhibitors (5-ARIs) are commonly used and widely available, with benefits observed from their effect on androgen signalling. Their effect relies on the inhibition of the 5-alpha reductase enzyme which aids in the conversion of testosterone to dihydrotestosterone.
Chislett B +5 more
europepmc +3 more sources
Contraindicated use of 5-alpha-reductase inhibitors in women. [PDF]
Br J Clin Pharmacol, 2017 Item does not contain ...
Teichert M +2 more
europepmc +7 more sources
Use of 5-alpha-reductase inhibitors did not increase the risk of cardiovascular diseases in patients with benign prostate hyperplasia: a five-year follow-up study. [PDF]
PLoS ONE, 2015 This nationwide population-based study investigated the risk of cardiovascular diseases after 5-alpha-reductase inhibitor therapy for benign prostate hyperplasia (BPH) using the National Health Insurance Research Database (NHIRD) in Taiwan.In total, 1 ...
Teng-Fu Hsieh +8 more
doaj +2 more sources
Prognostic influence of 5 alpha reductase inhibitors in patients with localized prostate cancer under active surveillance [PDF]
Urology Research and Practice, 2019 Objective: The incidence of prostate adenocarcinoma (PCa) is increased with the use of prostate-specific antigen (PSA). In the current study, we aimed to investigate the impact of 5- alpha- reductase inhibitors (5-ARI) on pathological progression in ...
Tayyar Alp Özkan +3 more
doaj +2 more sources